An understanding of glycoprotein IIb/IIIa inhibitor pharmacology and attention to patient-specific risk factors, access site management, and anticoagulant dosing can help minimize the bleeding ...

Eptifibatide, a platelet glycoprotein IIb/IIIa inhibitor substantially reduces ischemic complications in coronary stent interventions and could become a routine pre-treatment in stent coronary ...

Currently, three GPIIb/IIIa antagonists are available: abciximab, eptifibatide and tirofiban. Abciximab is a noncompetitive irreversible inhibitor of GPIIb/IIIa. It is the humanized chimeric Fab ...